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The family Anelloviridae includes human and animal torque teno viruses (TTVs) with extensive genetic diversity. The antigenic
diversity among anelloviruses has never been assessed. Using torque teno sus virus (TTSuV) as a model, we describe here the
first investigation of the antigenic relationships among different anelloviruses. Using a TTSuV genotype 1a (TTSuV1a) or
TTSuV1b enzyme-linked immunosorbent assay (ELISA) based on the respective putative ORF1 capsid antigen and TTSuV1-spe-
cific real-time PCR, the combined serological and virological profile of TTSuV1 infection in pigs was determined and compared
with that of TTSuV2. TTSuV1 is likely not associated with porcine circovirus-associated disease (PCVAD), because both the vi-
ral loads and antibody levels were not different between affected and unaffected pigs and because there was no synergistic effect
of concurrent PCV2/TTSuV1 infections. We did observe a higher correlation of IgG antibody levels between anti-TTSuV1a and
-TTSuV1b than between anti-TTSuV1a or -1b and anti-TTSuV2 antibodies in these sera, implying potential antigenic cross-
reactivity. To confirm this, rabbit antisera against the putative capsid proteins of TTSuV1a, TTSuV1b, or TTSuV2 were gener-
ated, and the antigenic relationships among these TTSuVs were analyzed by an ELISA and by an immunofluorescence assay
(IFA) using PK-15 cells transfected with one of the three TTSuVORF1 constructs. The results demonstrate antigenic cross-
reactivity between the two genotypes TTSuV1a and TTSuV1b but not between the two species TTSuV1a or -1b and TTSuV2.
Furthermore, an anti-genogroup 1 human TTV antiserum did not react with any of the three TTSuV antigens. These results
have important implications for an understanding of the diversity of anelloviruses as well as for the classification and vaccine
development of TTSuVs.
The first anellovirus was discovered in a Japanese patient withposttransfusion non-A to -E hepatitis in 1997 and termed
torque teno virus (TTV) (26, 27). Since then, a variety of anello-
viruses have been identified in numerous animal species, includ-
ing nonhuman primates, tupaias, pigs, cats, and dogs (3, 28).
Anelloviruses are small, single-stranded, circular DNA viruses
with genome sizes ranging from 2.0 to 3.9 kb (3, 27, 28). Recently,
the International Committee on Taxonomy of Viruses (ICTV)
established a new family,Anelloviridae, which comprises nine gen-
era, to include all human and animal anelloviruses (4). The vi-
ruses in this family show an extremely high degree of genetic
diversity (2, 27). For example, human TTVs were previously
classified into five different genogroups with approximately
50% nucleotide sequence differences, including at least 39 dis-
tinct genotypes with 30% nucleotide sequence differences
(27). In the most recent classification system, human TTV be-
longs to the genus Alphatorquevirus and contains 29 different
species (4).
The diversity of anelloviruses was exhibited not only in the
nucleotide sequence, genomic size, and animal hosts but also in
the presence of a number of intragenomic rearranged subviral
molecules in a single individual according to a study of human
TTV reported previously (7, 20). It was also hypothesized that
human TTV should display a high level of antigenic diversity due
to extensive genetic heterogeneity (21). However, experimental
evidence supporting such a hypothesis is still lacking thus far.
Porcine anellovirus or Torque teno sus virus (TTSuV) resem-
bles the genomic organization of humanTTV and is classified into
the genus Iotatorquevirus. TTSuV comprises two species, TTSuV1
and TTSuV2, each with a genomic size of approximately 2.8 kb
andwith at least four putative open reading frames (ORFs),ORF1,
ORF2, ORF1/1, and ORF2/2 (15, 16, 29). ORF1 of TTSuV is be-
lieved to encode a capsid protein with the largest size relative to
those of the four predicted viral proteins (5, 14, 15). TTSuV1
consists of at least two genotypes, TTSuV genotype (TTSuV1a)
and TTSuV1b, with 30% nucleotide sequence differences,
whereas TTSuV2 has only one genotype, including at least three
subtypes with15% nucleotide sequence differences (5, 15).
Multiple infections of human TTV with different genotypes in
a single human individual or TTSuV with different genotypes or
subtypes in a single pig have been documented (2, 10, 11, 15, 17,
23, 25). These findings raise the question of whether the anti-
ORF1 capsid antibodies recognized by the antigen from a partic-
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ular TTV or TTSuV species/genotype also comprise anti-ORF1
antibodies against other distinct TTV or TTSuV species/geno-
types and whether the anti-ORF1 antibodies from one TTV or
TTSuV genotype can cross-protect against infection with another
genotype. To our knowledge, for humanTTVorTTSuV infection,
there has been no information on this topic available to date.
Furthermore, the antigenic diversity and relationship of anellovi-
ruses have never been assessed (21). It is reasonable to speculate
that there is little, if any, antigenic cross-reactivity between differ-
ent anellovirus species/genotypes, due to the fact that concurrent
infections with multiple anelloviruses in a single individual or
animal exist.
We have previously developed and validated serum Western
blot (WB) assays and indirect enzyme-linked immunosorbent as-
says (ELISAs) for the detection of the IgG antibody against
TTSuV2 in porcine sera using the purified recombinant TTSuV2-
ORF1protein expressed inEscherichia coli (14). By usingTTSuV2-
specific real-time quantitative PCR (qPCR) and ELISA, we further
presented the combined virological and serological profile of
TTSuV2 infection under natural or diseased conditions using 160
porcine sera collected from different sources (14). In the present
study,we initially aimed to assess the serological profiles of the two
TTSuV1 genotypes (TTSuV1a and TTSuV1b) in pigs. Subse-
quently, we aimed to compare the virological and serological pro-
files of TTSuV1a and TTSuV1b with that of TTSuV2 and to deter-
mine the degree of correlation of IgG antibody levels between
anti-TTSuV1a and -TTSuV1b and between anti-TTSuV1a or -1b
and anti-TTSuV2 antibodies. Finally, for the first time, we as-
sessed the antigenic relationships between two TTSuV1 genotypes
(TTSuV1a and TTSuV1b), between two species (TTSuV1 and
TTSuV2), and between porcine and human genogroup 1 anello-
viruses using ELISAs and immunofluorescence assays (IFAs) with
antibody cross-reactions in PK-15 cells transfected with recombi-
nant plasmids expressing the ORF1 proteins from TTSuV1a,
TTSuV1b, and TTSuV2, respectively.
MATERIALS AND METHODS
Cell line.Aporcine circovirus type 1 (PCV1)-free porcine kidney cell line,
PK-15, was used in this study (9). Cells were grown in modified Eagle’s
medium supplemented with 10% fetal bovine serum and antibiotics at
37°C.
Sources of porcine sera. The porcine sera used in this study were
described previously (14). Briefly, serum samples for WB analysis were
collected from 20 conventional adult boars with no clinical symptoms
fromaVirginia pig farm; 7 gnotobiotic pigs fromVirginia (pigs 4 to 7, 224,
229, and 230; kindly provided by Lijuan Yuan and Guohua Li from
Virginia Tech) and 12 from Iowa (group D); 5 cesarean-derived, co-
lostrum-deprived pigs; and approximately 50 conventional piglets
from a Wisconsin pig farm. TTSuV2-seropositive porcine serum,
which was manufactured in New Zealand and free of all known OIE
(World Organization for Animal Health)-notifiable diseases, was also
used in this study.
One hundred sixty porcine serum samples were used for assessing the
virological and serological profiles of TTSuV1a and TTSuV1b infections
and were divided into five groups (groups A to E), as described previously
(14): (i) 20 group A samples were obtained from 10 specific-pathogen-
free (SPF) pigs (60 to 80 days old at arrival) free of known pathogens and
were collected upon arrival at the facility and 2months after arrival; (ii) 60
group B samples were collected from 105-day-old pigs in a farm with an
outbreak of porcine circovirus-associated disease (PCVAD), including 30
samples from clinically affected pigs and 30 from clinically unaffected
pigs; (iii) 58 group C samples were collected from 28-day-old pigs of an
unknown disease status, 28 from clinically affected and 30 from clinically
unaffected pigs; (iv) 12 group D samples were obtained from 14- to 42-
day-old gnotobiotic pigs located in Iowa; and (v) 10 group E sera were
obtained from 21- to 30-day-old SPF pigs used for an experimental PCV2
infection study.
Construction of the TTSuV1a- and TTSuV1b-ORF1 expression
plasmids. TheC-terminal part of theORF1 proteins of twoTTSuV1 strains,
PTTV1a-VA (GenBank accession no. GU456383) and PTTV1b-VA (Gen-
Bank accession no. GU456384), was amplified from the available PCR frag-
ments reportedpreviously (15).Theampliconwas expected toencodea trun-
cated PTTV1a-VA ORF1 protein of 319 amino acids (aa) (positions 317 to
635 corresponding to PTTV1a-VA) or a truncated PTTV1b-VA ORF1 pro-
tein of 318 aa (positions 322 to 639 corresponding to PTTV1b-VA). An ad-
ditional methionine codon was introduced at the N terminus of each ampli-
fied fragment. TwoORF1 expression plasmids, designated pTri-1aORF1 and
pTri-1bORF1, were each constructed by cloning the respective PCR product
into a bacterial/insect/mammalian-triple expression vector, pTriEx1.1-Neo
(Novagen), between the NcoI and XhoI restriction sites to generate two C-
terminally 8His-tagged fusion proteins. The recombinant plasmids were
confirmed by DNA sequencing. The TTSuV2 ORF1 expression construct
pTri-2cORF1 was described previously (14).
Expression and purification of the recombinant TTSuV1a- and
TTSuV1b-ORF1 proteins. The two plasmids were each transformed into
Rosetta 2(DE3)(pLacI) competent cells (Novagen, San Diego, CA). The
bacteria were grown in 100 ml of Overnight Express TB medium (Nova-
gen) for 16 to 18 h at 37°C, and the bacterial culture was then harvested by
centrifugation at 3,400 rpm for 15 min at 4°C. The resulting bacterial
pellet was treated with BugBuster and rLysozyme according to the man-
ufacturer’s protocol (Novagen). Benzonase nuclease (Novagen) was
added to degrade DNA and RNA. The resulting inclusion bodies were
lysed in a solution containing 6 M guanidine hydrochloride, 0.1 M so-
dium phosphate, 0.01 M Tris-chloride, and 0.01 M imidazole with a pH
value of 8.0. The lysate supernatants were collected by centrifugation and
were used forHis-tagged protein purificationwith 50%Ni-nitrilotriacetic
acid (NTA)HisBind resin (Novagen) under denaturing conditions with 8
M urea. Proteins were dialyzed as described previously (14). The recom-
binant His-tagged TTSuV1a- or TTSuV1b-ORF1 proteins used as the
antigens for ELISAs and rabbit immunization were quantified by using
NanoDrop spectrophotometry and frozen at80°C until use.
Generation of anti-ORF1 antisera against TTSuV1a and TTSuV1b
in rabbits. The two ORF1 proteins of TTSuV1a and TTSuV1b expressed
in E. coli were purified and used to immunize two New Zealand White
rabbits using a custom antibody production service at Rockland Immu-
nochemicals (Gilbertsville, PA). Antisera were harvested at 50 days
postimmunization.
SDS-PAGE, anti-His-taggedMAbWB, and serumWBanalyses.The
unpurified or purified recombinant TTSuV1 ORF1 proteins were re-
solved on a 4 to 12% Bis-Tris polyacrylamide gel (Invitrogen, Carlsbad,
CA) by electrophoresis and were subsequently transferred onto a polyvi-
nylidene difluoride (PVDF) membrane. Proteins were detected on the
PVDF membrane by using an anti-6His-tagged monoclonal antibody
(MAb) at a 1:1,000 dilution at 4°C, followed by incubation with IRDye
800CW-conjugated goat anti-rabbit IgG (Li-Cor Biosciences, Lincoln,
NE) at a 1:10,000 dilution at room temperature. After three washing steps
using Tris-buffered saline–0.05% Tween 20 (TBS-T), the membrane was
analyzed by using the Odyssey infrared imaging system (Li-Cor Biosci-
ences).
For serum WB analysis, the purified TTSuV1a- or TTSuV1b-ORF1
proteins were incubated with individual porcine sera at a 1:200 dilution
and with IRDye 800CW-conjugated rabbit F(ab=)2 anti-swine IgG (Rock-
land Immunochemicals, Inc.) at a 1:10,000 dilution at room temperature.
The membrane was then analyzed by using the Odyssey infrared imaging
system.
Indirect ELISAs. TTSuV1a- and TTSuV1b-based ELISAs were devel-
oped. The optimal concentrations of the antigens and the optimal dilu-
Serological Proﬁle and Antigenic Difference of TTSuVs
October 2012 Volume 86 Number 19 jvi.asm.org 10629
tions of sera and horseradish peroxidase (HRP) conjugates were deter-
mined by checkerboard titrations. Similar to a TTSuV2-based ELISA
reported previously (14), the optimal amount of the ORF1 antigen of
TTSuV1a or TTSuV1bwas 68 ng per well. The optimal ELISA results were
obtained by using a 1:100 dilution of serum samples and a 1:4,000 dilution
of IgG conjugates.
The ELISA was initiated by diluting the purified ORF1 proteins into
carbonate coating buffer (pH 9.6), which was used for coating 96-well
ELISA plates (Greiner Bio-One, Monroe, NC) with 100 l/well. After
incubation at 37°C for 2 h, each well was washed 3 times with 300 l of
TBS-T and blocked with protein-free blocking buffer (Pierce, Rockford,
IL) in a volume of 300l for 1 h at 37°C. One hundredmicroliters of each
diluted serum sample was transferred into the corresponding well on the
ELISA plates and incubated at 37°C for 2 h. After the wells were washed
three times with 300 l of TBS-T buffer, the diluted HRP-conjugated
rabbit anti-swine IgG (Rockland) was added to each well in a volume of
100 l, and the plate was incubated at 37°C for 1 h. A volume of 100 l of
Sure Blue Reserve 1-Component (KPL, Gaithersburg, MD) was added to
eachwell and incubated for 10min at room temperature. The reactionwas
stopped by the addition of 100 l/well of 1 N HCl. The plates were then
read at 450 nmby using a spectrophotometer. All serum samples were run
in duplicates. Positive and negative controls run in quadruplicates were
included on each plate. In general, the mean OD value of the negative
control was less than 0.5, whereas the mean OD value of the positive
control was greater than 1.5. The ELISA value was calculated as the S/N
value, which was expressed as a ratio of the mean OD value of a sample to
themeanODvalue of the negative control (n 4). A subjective cutoff S/N
value of 1.2 was used to distinguish between positive and negative sam-
ples.
Real-time qPCR assay for quantitation of TTSuV1. A SYBR green-
based TTSuV1-specific real-time qPCR developed recently in our labora-
torywas used tomeasure the total TTSuV1 viral loads (bothTTSuV1a and
TTSuV1b) in the five groups of pig sera, as described previously (13).
Since some of the samples were run with standards with a detection limit
of 1.0 103 copies/ml, while other samples were run with standards with
a detection limit of 1.0 104 copies/ml, to normalize the final results, the
minimal detection limit was set to 1.0  104 copies per ml in this study.
The TTSuV1 qPCR assay does not cross-amplify TTSuV2 DNA (13). The
quantitation of TTSuV2 and PCV2 viral loads in group B sera was re-
ported previously (14).
Statistical analyses. Data were analyzed by using SAS software (ver-
sion 9.2; SAS Institute, Inc., Cary, NC) and GraphPad Prism software
(version 5.0; GraphPad, San Diego, CA). Antibody levels (represented by
S/Nvalues)were compared between categories of log10 viral titers by using
the Kruskal-Wallis test followed by Dunn’s procedure. For each group
that contained clinically affected and nonaffected pigs (groups B and C),
log10 virus titers of pigs with and pigs without clinical signs were com-
pared by using a Wilcoxon two-sample test. Antibody levels of pigs with
and those without disease were compared by using a two-sample t test.
Using a cutoff point of 1.2, the proportions of affected and unaffected pigs
with antibodies were compared by using a Fisher exact test.
Correlations between S/N values for TTSuV1a and S/N values for
TTSuV1b and between S/N values for TTSuV1a or TTSuV1b (separately)
and TTSuV2 were assessed by using Spearman’s correlation coefficient.
The correlations were separately generated for a combination of 3 groups
(group A to group C).
To assess the synergistic effects of PCV2 and TTSuV1 on disease prev-
alence, the pigs in group B were categorized as follows: pigs positive for
both PCV2 and TTSuV1, pigs positive for PCV2 only, pigs positive for
TTSuV1 only, and pigs with neither PCV2 nor TTV1 infection. Subse-
quently, the proportions of affected pigs were compared between groups
by using Fisher’s exact test. Statistical significancewas set to an alpha value
of 0.05.
Transfection of PK-15 cells with TTSuV expression constructs.
PK-15 cells were seeded onto a 6-well plate and grown until they reached
70% to 80% confluence before transfection. Two micrograms of each of
the three constructs pTri-1aORF1, pTri-1bORF1, and pTri-2cORF1,
mixedwith 10l of Lipofectamine LTX (Invitrogen), was transfected into
the cells. Cells were cultured for 3 days andwere subjected to IFA to detect
ORF1 expression.
IFA. Five rabbit antisera were used for IFA staining: anti-TTSuV1a,
anti-TTSuV1b, anti-TTSuV2 antisera; prebleed rabbit negative-control
serum; and rabbit anti-human genogroup 1TTVORF1 antiserum (AK47;
a generous gift from Annette Mankertz at the Robert Koch Institute, Ber-
lin, Germany) (22). The AK47 antiserum was also produced in rabbits
immunized with a C-terminal fragment (aa 402 to 733) of ORF1 of strain
P/1C1 (GenBank accession no. AF298585). Transfected cells were fixed
with acetone. Five hundred microliters of each of the five antisera, at a
1:500 dilution in phosphate-buffered saline (PBS), was added on top of
the cells in each well and incubated for 1 h at room temperature. After
three washing steps with PBS, the cells were incubated with 500 l Alexa
Fluor 488-labeled goat anti-rabbit IgG (Invitrogen) at a 1:200 dilution for
1 h of incubation at room temperature. Cells were stained with 500 l
4=,6-diamidino-2-phenylindole (DAPI) (KPL, Inc.) at a 1:1,000 dilution
and visualized under a fluorescence microscope.
RESULTS
Expression and purification of the N-terminally truncated
TTSuV1a and TTSuV1b ORF1 proteins. Previously, we success-
fully expressed a truncated TTSuV2 ORF1 protein in E. coli (14).
Using a similar strategy, the C-terminal region of the TTSuV1a
ORF1 (1a-ORF1) or TTSuV1b ORF1 gene with a C-terminally
engineered 8His tag was inserted into the triple expression vec-
tor pTriEx1.1-Neo, resulting in two recombinant constructs,
pTri-1aORF1 and pTri-1bORF1. We also constructed an ORF1
C-terminally truncated version of 1b-ORF1 as a control, termed
pTri-1bORF1-ctruc (1bORF1-ctruc), which is 71 aa shorter than
1b-ORF1, to compare the size with that of pTri-1bORF1 by SDS-
PAGE and WB analyses.
The three recombinant proteins 1a-ORF1, 1b-ORF1, and
1bORF1-ctruc were found to be insoluble and were expressed
within the bacteria as inclusion bodies. The purification of the
crude lysates from 1a-ORF1 products with a nickel affinity col-
umn resulted in the visualization of two bands of 40 kDa (Fig.
1A, white arrowheads) and70 kDa (black arrowheads), as ana-
lyzed by Coomassie blue staining (Fig. 1A). The40-kDa band is
the expected product of the truncated 1a-ORF1 protein, whereas
the 70-kDa polypeptide is an unknown product but should be
derived from the former, since it also reacted with an anti-His-
taggedMAb (see below). The expression of 1b-ORF1 or 1bORF1-
ctruc showed a smear in the crude lysates (Fig. 1B). After purifi-
cation, two bands of40 kDa and70 kDa, similar to 1a-ORF1,
were also identified in the purified 1b sample, whereas only a
30-kDa polypeptide (Fig. 1B, white arrowheads) was detected in
the purified 1b-ctruc sample (Fig. 1B). The bands of40 kDa and
30 kDa were consistent with the expected sizes of the 1b-ORF1
and 1bORF1-ctruc protein products, respectively. All the identi-
fied polypeptides in the purified products were detected by WB
using the anti-His-tagged MAb (Fig. 1C). The results indicated
that both the truncated 1a-ORF1 and 1b-ORF1 proteins were suc-
cessfully expressed in E. coli and thus can be used as antigens for
TTSuV1a and TTSuV1b antibody detection in porcine sera.
Development of TTSuV1a- and TTSuV1b-based serum WB
and indirect ELISAs. In order to identify reference positive and
negative sera as controls, a total of 100 serum samples from dif-
ferent sources, including those from the gnotobiotic pigs, were
collected. Samples were screened for anti-TTSuV1a or anti-
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TTSuV1b IgG seropositivity by serumWB analysis using purified
1a-ORF1 or 1b-ORF1 as the antigen, respectively. A TTSuV2-
seropositive and TTSuV1/TTSuV2 DNA-positive porcine serum
sample (16) showed reactivity with the 1a-ORF1 and the 1b-ORF1
antigens, as the 40-kDa band was present in the WB analysis
(Fig. 2A, rightmost two lanes). Therefore, this serum was consid-
ered to be TTSuV1a and TTSuV1b seropositive and thus was used
as a reference positive control for the ELISAs. All the 7 Virginia
and 12 Iowa gnotobiotic pigs had no detectable TTSuV1a and
TTSuV1b antibodies (Fig. 2A). Except for a few serum samples
from conventional pigs from a Wisconsin swine farm (Fig. 2B,
leftmost two lanes), the remaining samples tested positive for both
TTSuV1a and TTSuV1b antibodies by WB analysis. The dual-
negative serum samples from the conventional pigs fromWiscon-
sin were pooled and used as negative-control reference serum.
With the available positive- and negative-control reference
sera, TTSuV1a- and TTSuV1b-based ELISAs were subsequently
developed and standardized, respectively. The concentrations of
the purified 1a-ORF1 or 1b-ORF1 antigen, porcine sera, and the
IgG conjugate were determined by a checkerboard titration assay
to ensure a low background signal and to give the highest differ-
ence in OD at 450 nm (OD450) values between the positive and
negative controls. WB-negative gnotobiotic porcine sera showed
very low OD values (0.1) compared to that of the negative-
control reference serum (Fig. 2C), suggesting that these pig sera
should not serve as a negative-control reference for the detection
of porcine field samples in the ELISA.
TTSuV1 viral DNA loads and anti-TTSuV1a and anti-
TTSuV1b IgG antibody levels.A total of 160 serum samples were
collected and evaluated for the prevalence and viral DNA load of
TTSuV1 by real-time qPCR and for seroprevalence and antibody
levels (represented by S/N values) of anti-TTSuV1a and anti-
TTSuV1b IgG antibodies by the ELISAs. Among the 160 samples,
138 sera in groups A to C were collected from three herds under
field conditions, whereas the remaining 22 sera from groups D
(gnotobiotic pigs) and E were collected from pigs raised and
housed under strictly controlled experimental conditions in re-
search facilities.
None of the 12 TTSuV1a/TTSuV1b-seronegative gnotobiotic
pigs in group D had detectable viremia. In group E pigs, only one
pig was viremic, whereas six were seropositive for TTSuV1a, and
among them, one pig was also seropositive for TTSuV1b.
In groups A and C, 44 of 138 pigs were viremic (31.9%), whereas
128 were TTSuV1a seropositive (92.8%) and 121 were TTSuV1b se-
ropositive (87.7%) (Table 1). The incidence of TTSuV1 viremia was
much lower than the TTSuV1a- or 1b-seropositive rate, suggesting a
previous clearance of the virus by neutralizing antibodies during the
post-TTSuV1 infection convalescent period.
All three markers of TTSuV1 infection, TTSuV1 DNA and
TTSuV1a/1b antibodies, were found in 40 serum samples. Nota-
bly, the number of pigs that were dually TTSuV1a/TTSuV1b se-
ropositive but viral DNA negative (77 samples) was higher than
the number of pigs with TTSuV1a or TTSuV1b seropositivity only
(Table 1). In addition, the total number of porcine sera with both
antibodies was 117 (40 plus 77) among the 138 serum samples,
implying that (i) coinfection rates of pigs with TTSuV1a and
TTSuV1b are high, which was expected, and/or (ii) a certain de-
gree of cross-reactivitymay exist between anti-TTSuV1a and anti-
TTSuV1b IgG antibodies.
We previously demonstrated that, over a 2-month period, the
10 group A pigs had decreasing TTSuV2 viral loads that were
associated with elevated anti-TTSuV2 ORF1 IgG antibody levels
(14). Whether an analogous situation for TTSuV1 in these 10
pigs existed was subsequently analyzed in this study by com-
paring the TTSuV1 viral DNA loads and the anti-TTSuV1a or
anti-TTSuV1b antibody levels in sera from the time of their
arrival until 2 months later. Both the anti-TTSuV1a and anti-
TTSuV1b antibody titers increased in all 10 pigs (Fig. 3). Five of
the 10 pigs had undetectable TTSuV1 DNA levels during the 2
months, and in 4 pigs, the viral DNA loads decreased after 2
months, including 3 pigs with no detectable TTSuV1 DNA
(data not shown). These results were consistent with those of
the TTSuV2 study. Low levels of serum TTSuV DNA that are
beyond the detection limit of the qPCR may explain why some
pigs are negative for TTSuV DNA even though they develop
antibodies.
FIG 1 Expression and purification of the amino-terminally truncated TTSuV1a and TTSuV1b ORF1 proteins. (A) SDS-PAGE analysis of unpurified and
purified TTSuV1a-ORF1 products. (B) SDS-PAGE analysis of unpurified and purified TTSuV1b-ORF1 products. An amino- and carboxyl-terminally double-
truncated TTSuV1b-ORF1 (1b-ctruc) of a smaller product size served as the control. (C) Near-infrared fluorescent WB analysis of purified 1a- and 1b-ORF1
products using an anti-His-tagged MAb. Open arrowheads indicate the truncated ORF1 protein of the expected size, whereas filled arrowheads show the
presumed homodimers of the expected proteins. M, protein markers.
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TTSuV1 is likely not associated with PCVAD. Although
PCV2 is considered the primary causative agent for the induction
of clinical PCVAD, it was recently shown that TTSuV partially
contributed to the experimental induction of PCVAD in pigs (8).
It was also observed that PCVAD-affected pigs with low or no
detectable PCV2 infection had a higher TTSuV2 DNA prevalence
than non-PMWS-affected pigs in Spain (19). We previously
found that PCVAD-affected pigs had a significantly lower level of
TTSuV2 antibody than did PCVAD-unaffected pigs in group B
(14). However, determinations of the levels of anti-TTSuV1a and
anti-TTSuV1b IgG antibodies in these serum samples did not re-
veal a difference between the PCVAD-affected and -unaffected
pigs (Fig. 4). In addition, there was no statistically significant dif-
ference in TTSuV1 viral loads between the PCVAD-affected and
TABLE 1 Distribution of TTSuV1 viremia and anti-TTSuV1a and anti-
TTSuV1b IgG antibodies among 138 serum samples from three
different herds
No. of
samples
with
profile
Distribution of results
TTSuV1 viremia
(31.9% positive;
44/138)
Anti-TTSuV1a
IgG (92.8%
positive; 128/138)
Anti-TTSuV1b
IgG (87.7%
positive; 121/138)
40   
2   
2   
0   
77   
9   
2   
6   
FIG 2 TTSuV1a or TTSuV1b serum WB and ELISA. (A) WB analyses using gnotobiotic pig serum samples from Virginia and commercial OIE disease-free
porcine serum as the positive-control reference serum (pos). (B) Representative results of TTSuV1a WB analyses of conventional pig sera from a farm in
Wisconsin. Purified 1a-ORF1 protein was used as the antigen. Sera that tested negative for both TTSuV1a and TTSuV1b antibodies byWBwere pooled and used
as the negative-control reference serum. Open arrowheads indicate the truncated ORF1 protein of the expected size. Only the bands in green were considered
positive. M, protein markers. (C) TTSuV1a or TTSuV1b ELISA results for the seven Virginia gnotobiotic pig serum samples and positive- and negative-control
reference sera.
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-unaffected pigs (see Fig. S2A in the supplemental material). In
contrast, the PCV2 viral loadwas significantly higher (P 0.05) in
PCVAD-affected pigs than in PCVAD-unaffected pigs (see Fig.
S2B in the supplemental material).
WefurtheranalyzedwhetherthereexistedasynergisticeffectofPCV2
andTTSuV1associatedwithPCVAD.SerumviralDNAprevalencerates
(viremia) of PCVAD-affected pigs were as follows: 50% (16/32) for
PCV2 andTTSuV1, 56% (14/25) for PCV2 only, 0% (0/1) for TTSuV1
only, and 0% (0/2) for no detectable virus. These proportions were not
significantly different (P  0.4339). The above-described results sug-
gested that TTSuV1 is likely not associatedwithPCVAD.
Comparison and correlations of seroprevalence and anti-
body levels among anti-TTSuV1a, anti-TTSuV1b, and anti-
TTSuV2 antibodies. Mixed infections by TTSuV1 and TTSuV2
are common in pigs, as determined by the presence of viral DNAs
of both TTSuV1 and TTSuV2 in the same pig using PCR (11,
13–15). In this study, we provided serological evidence to support
this conclusion by analyzing the seroprevalence distributions of anti-
TTSuV1a, -TTSuV1b, and -TTSuV2 IgG antibodies in 138 serum
samples from groups A to C. As shown in Fig. 5A, 82 of 138 serum
samples were triple seropositive, indicating that these pigs had been
infected by TTSuV1 (TTSuV1a and/or TTSuV1b) and TTSuV2.
The distributions of dual-seropositive samples were signifi-
cantly different. A total of 117 (82 plus 30 plus 5) porcine serawere
dually seropositive for both anti-TTSuV1a and anti-TTSuV1b an-
tibodies, which was consistent with the number calculated in Ta-
ble 1. In contrast, dual seropositivity to anti-TTSuV1a and anti-
TTSuV2 antibodies or to anti-TTSuV1b and anti-TTSuV2
antibodies occurred in only one sample each (Fig. 5A).
Furthermore, the correlations of antibody levels between anti-
FIG 3 Retrospective evaluation of levels of TTSuV1 antibody to the ORF1 proteins of TTSuV1a (A) and TTSuV1b (B) in 10 pigs from group A from the time of
their arrival at the research facility to 2 months after arrival.
FIG 4 Box plots showing comparisons of anti-TTSuV1a (A) and anti-TTSuV1b (B) ORF1 antibody levels between PCVAD-affected and -unaffected pigs.
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TTSuV1a and anti-TTSuV1b, between anti-TTSuV1a and anti-
TTSuV2, and between anti-TTSuV1b and anti-TTSuV2 antibod-
ies were assessed for the 138 serum samples by using Spearman’s
correlation coefficient. A good linear relationship between the an-
ti-TTSuV1a and anti-TTSuV1b antibodies was observed (Spear-
man’s rank correlation coefficient of 0.91; P 0.0001) (Fig. 5B).
When all 160 samples were included, a better agreement was ob-
tained (Spearman’s rank correlation coefficient of 0.93; P 
0.0001). A lesser degree of correlation between anti-TTSuV1a and
anti-TTSuV2 or between anti-TTSuV1b and anti-TTSuV2 anti-
bodies was found than the degree of correlation between anti-
TTSuV1a and anti-TTSuV1b antibodies (data not shown). The
results further revealed an association of seroprevalence and anti-
body levels between anti-TTSuV1a and anti-TTSuV1b antibodies,
and thus, it is logical to hypothesize that there exists antigenic
cross-reactivity between genotypes TTSuV1a and TTSuV1b.
AnalysisofantigenicrelationshipsamongTTSuV1a,TTSuV1b,
and TTSuV2 by ELISA. Three antisera against the truncated re-
combinantORF1s of TTSuV1a, TTSuV1b, or TTSuV2were raised
by the immunization of rabbits with the respective purified re-
combinant antigens. The specificity of these antisera was demon-
strated by WB analysis using the TTSuV ORF1 antigens and the
bacterial control (cell lysis product from bacteria harboring the
empty expression vector) as well as by transfection experiments
with PK-15 cells (see below) with the TTSuV ORF1 expression
construct pTriEx1.1-Neo (see Fig. S1 in the supplemental mate-
rial) (15).
Cross-immunoreactivity studies were initially performed to
assess whether one of these antigens could cross-react with anti-
sera against the other two antigens in an ELISA format. The pre-
bleed rabbit serum was used as the negative control. As expected,
each of the three TTSuV antigens reacted with its corresponding
homologous antiserum but not with the prebleed negative-con-
trol serum (OD values of 0.1) that was serially diluted 1:200 to
1:1,600 (Fig. 6).
The TTSuV2 antigen did not appear to cross-react with
TTSuV1a or TTSuV1b antiserum even at a 1:200 dilution, since
the OD value was relatively low (Fig. 6C). In contrast, the
TTSuV1b antigen did cross-react with the anti-TTSuV1a serum
(as shown at 1:200 and 1:400 dilutions, both with OD values of
0.5) but not with the anti-TTSuV2 serum (Fig. 6B), whereas the
TTSuV1a antigen likely cross-reacted with the anti-TTSuV1b se-
rum (at a 1:200 dilution) but not with the anti-TTSuV2 serum
(Fig. 6A). The ELISA results strongly supported our hypothesis
that there is antigenic cross-reactivity between the two TTSuV1a
and TTSuV1b genotypes but not between the two species
TTSuV1a or -1b and TTSuV2.
Demonstration of antigenic relationships among TTSuV1a,
TTSuV1b, andTTSuV2andbetweenTTSuVsandagenogroup1
human TTV by IFA. In order to analyze the antigenic cross-reac-
tivity among these viruses more definitively, an antibody cross-
reactivity experiment was performed by using IFA staining. PK-15
cells were transfected with three plasmid constructs, pTri-
1aORF1, pTri-1bORF1, and pTri-2cORF1, which harbor the
truncated ORF1 capsid genes from TTSuV1a, TTSuV1b, and
TTSuV2, respectively. At 3 days posttransfection, cells were
stainedwith anti-TTSuV1a, anti-TTSuV1b, anti-TTSuV2 antisera
and prebleed serum. As shown in Fig. 7, cells transfected with
pTri-1aORF1 (Fig. 7A) or pTri-1bORF1 (Fig. 7B) stained positive
with both the anti-TTSuV1a and anti-TTSuV1b antisera but not
with the anti-TTSuV2 antiserum (Fig. 7A and B) or the prebleed
serum (data not shown), whereas cells transfected with pTri-
2cORF1 reacted only with the anti-TTSuV2 serum (Fig. 7C). Each
TTSuV1 antiserum reacted more strongly with its own homolo-
gous antigen than with the heterologous antigen based on a com-
parison of the positive cell numbers and fluorescence intensities
(Fig. 7A and B). The truncated ORF1 proteins were expressed in
both the nucleus and cytoplasm of the transfected cells (Fig. 7),
which was different from what we found for cells transfected with
full-length TTSuV DNA clones (16), probably due to the lack of
most of the putative nuclear localization signals (NLSs) located at
the N-terminal part of ORF1 in the truncated genes (by computer
analysis) (data not shown). Table 2 summarizes the results of the
cross-reactive immunostaining study. In addition, when trans-
fected cells were each stained with an anti-human genogroup 1
TTV ORF1 antiserum (AK47, raised in rabbits), no fluorescent
signal was detected. Mock-transfected cells did not stain with any
of the five antisera (Table 2). The IFA result further confirmed the
presence of antigenic cross-reactivity between TTSuV1a and
TTSuV1b, as shown by the ELISA, but not between TTSuV1a or
-1b and TTSuV2. The results also revealed that there was no anti-
genic cross-reactivity between genogroup 1 human TTV and por-
cine anelloviruses.
FIG 5 High correlation between anti-TTSuV1a and anti-TTSuV1b IgG anti-
bodies in 138 serum samples. (A) Distribution of anti-TTSuV1a, -TTSuV1b,
and -TTSuV2 IgG antibodies. (B) Scatter plots showing a good linear relation-
ship of antibody levels between anti-TTSuV1a and anti-TTSuV1b antibodies
(P 0.0001).
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Identificationof twoputative antigenic sites onORF1 shared
byTTSuV1a andTTSuV1bby sequence analyses.The full-length
ORF1 proteins of TTSuV1 and TTSuV2 shared only 22.4 to 25.8%
amino acid sequence identity, with no significantly conserved re-
gions being identified (15). The ORF1 proteins of the two TTSuV
species share only 19.1 to 21.0% amino acid sequence identity
with the sequence of human genogroup 1 TTV isolate P/1C1
(GenBank accession no. AF298585). The high degrees of ORF1
sequence divergences between TTSuV1 and TTSuV2 and between
porcine and human anelloviruses likely account for the absence of
antigenic cross-reactivity observed in this study.
However, the amino acid sequence identity of the ORF1 pro-
teins of genotypes TTSuV1a and TTSuV1b (six isolates available
in GenBank) ranged between 49.4 and 52.4%. We previously
found that conserved sites exist in the ORF1 proteins of different
TTSuV1 strains, except for the four proposed variable regions
(30.0 to 37.5% amino acid identity) (15). In order to identify the
common antigenic sites on ORF1 between genotypes TTSuV1a
and TTSuV1b, we performed a comparative analysis of the hydro-
philicity profiles of the ORF1 amino acid sequences between
PTTV1a-VA and PTTV1b-VA. Two conserved hydrophilic re-
gions located at themiddle andC-terminal regionswere identified
(Fig. 8). The C-terminal antigenic domain appeared to be more
antigenic than the domain in the middle region. An alignment of
the two putative antigenic regions among all published TTSuV1
sequences revealed a high degree of sequence conservation (data
not shown).
DISCUSSION
The immunology of anelloviruses is poorly understood (21). The
detection of specific adaptive immune responses can provide in-
sights into anellovirus epidemiology. By analogy to chicken ane-
mia virus (CAV), another single-stranded circular DNA virus, the
ORF1 product of anelloviruses is believed to function as the puta-
tive capsid protein and thus represents the major viral antigen (6,
21).
The detection of human TTV IgG antibodies in human popu-
lations based on human TTV ORF1 as the antigen was reported
previously (21). In most cases, the successful expression of the
human ORF1 antigen depends on the utilization of a strategy tar-
geting the C-terminal region (12, 18, 22, 30). Most recently, our
group successfully used theC-terminal fragment of theORF1 pro-
tein of a U.S. strain of TTSuV2 as the antigen to detect TTSuV2-
specific IgG antibodies in pig sera by an ELISA (14). Together with
the present study, for serological detections of the two porcine
TTV species 1 genotypes TTSuV1a and TTSuV1b, the obtained
data suggest that the C-terminal portion of the ORF1 proteins of
anelloviruses is an appropriate target for the development of se-
rodiagnostic assays.
Indeed, based on the CAV virion structure determined by
cryo-electron microscopic images, the C-terminal half of ORF1
was proposed to form the outer part of the capsid that is exposed
to the virion surface, whereas the basic N-terminal part of CAV
ORF1 was proposed to be inside the capsid to bind the viral DNA,
and themiddle part of ORF1 was proposed to form the inner shell
of the capsid (6). The ORF1 polypeptide of anelloviruses was sug-
gested previously to be organized in the same way as that of CAV
(6). This proposed structure is consistentwith a computer analysis
of the ORF1 hydrophilicity profiles of TTSuV1 (Fig. 8) and
TTSuV2 (14). In either case, there are two conserved major hy-
drophilic regions located at the middle and C-terminal regions
that span the C-terminal half of ORF1 (14).
The reliability and specificity of the established ELISAs for dif-
ferential TTSuV antibody detection were guaranteed by the
screening of positive and negative reference sera through serum
WB. This was further demonstrated by the triple seronegativity of
TTSuV1a, TTSuV1b, and TTSuV2 in gnotobiotic pigs of group D
FIG 6 Reactivities of the three purified TTSuV ORF1 antigens of TTSuV1a
(A), TTSuV1b (B), and TTSuV2 (C) with rabbit antisera against ORF1 of
TTSuV1a, TTSuV1b, or TTSuV2 or with prebleed rabbit serum with 2-fold
serial dilutions by ELISAs. Each antigen was tested against each serum sample
in duplicate. Mean OD values are presented. Ab, antibody.
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(Fig. 2). However, it should be noted that the current definition of
the cutoff value (S/N  1.2) for the ELISAs may not completely
normalize plate-to-plate variations. In a previous study, we uti-
lized amore appropriate cutoff definition (themean value of neg-
ative controls plus three times the standard deviation) for the
TTSuV2 ELISA (14). Therefore, the cutoff value in this study may
not cover 100% of the truly negative individuals in a given popu-
lation. Future improvements of the TTSuV1 ELISA should in-
FIG 7 Immunofluorescence assay (IFA) results for PCV1-free PK-15 cells transfected with plasmid pTri-1aORF1 (A), pTri-1bORF1 (B), or pTri-2cORF1 (C)
at 3 days posttransfection. pTri-1aORF1-, pTri-1bORF1-, or pTri-2cORF1-transfected cells were stained with rabbit anti-TTSuV1a, anti-TTSuV1b, and anti-
TTSuV2 ORF1 antisera, respectively. Alexa Fluor 488-conjugated goat anti-rabbit IgG (green) was used as the secondary antibody in the IFA. Antibody staining
merged with nuclear staining using DAPI (blue) is also shown. Magnification,200.
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clude additional negative samples in every plate to allow for the
determination of a more appropriate cutoff value. The presently
reported ELISA results were checked for cross-reactivity byWest-
ern blot analyses of sera.
The viremia rate of TTSuV1 was low (31.9%) in comparison
with that of TTSuV2 (59.9%) (14) in the 138 pigs. This may result
from the low sensitivity of the TTSuV1 qPCR assay (10 copies/l),
the potential absence of extracted viral DNA from sera due to the
cell-associated circulation of TTSuV1 in blood, or both. There-
fore, by utilizing amore sensitive real-time qPCR assay such as the
TaqMan probe-based approach or setting up an internal control
for qPCR quantification using heparinized blood or plasma sam-
ples to test whether TTSuV is hidden in blood cells in a latent state
will be needed in future studies.
A high seropositive rate for TTSuV1a (92.8%) or TTSuV1b
(87.7%) was revealed in the 138 pigs of groups A to C (Table 1),
whichwas higher than that for TTSuV2 (60%) (14), indicating a
wider spread of actual TTSuV1 infection or the presence of long-
persisting anti-TTSuV1 ORF1 antibodies in these pigs regardless
of a low incidence of TTSuV1 viremia. Accordingly, these results,
for the first time, provided serological evidence supporting dual
infections by TTSuV1 and TTSuV2 in the same pigs. To our
knowledge, this is also the first study demonstrating dual anellovirus
infections in the same animals by using serological diagnosis in addi-
tion to the PCR assay. Therefore, the subsequent question raised was
to determine the specificity of the seropositivity and cross-antigenic
reactivity among different TTSuV species and genotypes.
In this study, we demonstrated by investigating four different
aspects that, indeed, there exists antigenic cross-reactivity be-
tween genotypes TTSuV1a andTTSuV1b but not between the two
TTSuV species (TTSuV1a or -1b andTTSuV2). First, compared to
the serum samples with single TTSuV1a or TTSuV1b seropositiv-
ity, the number of serum samples with TTSuV1a/1b dual seropos-
itivity was much higher (Table 1), likely implying a certain degree
of cross-antigenic reactivity between the TTSuV1a and TTSuV1b
antibodies. Second, the number of serum samples with dual
TTSuV1a and TTSuV1b seropositivity was significantly higher
than the number of samples with dual seropositivity to TTSuV1a
and TTSuV2 or to TTSuV1b and TTSuV2 (Fig. 5A). In addition, a
high correlation of antibody levels between anti-TTSuV1a and
anti-TTSuV1b antisera, as assessed by Spearman’s correlation co-
efficient, was observed (Fig. 5B). These analyses were conducted
under the background of multiple TTSuV infections in field sam-
ples, which led us to propose a logical hypothesis regarding the
presence of antigenic cross-reactivity between TTSuV1a and
TTSuV1b. Third, this hypothesis was experimentally confirmed
by an analysis of the antigenic relationships among TTSuV1a,
TTSuV1b, and TTSuV2 through antigen-specific ELISAs (Fig. 6)
and antibody cross-reactivity studies using PK-15 cells transfected
with the three TTSuV ORF1 constructs, respectively (Fig. 7 and
Table 2). Finally, a sequence comparison of ORF1 proteins of
TTSuVs also supported the observed epidemiologic and experi-
mental data in this study: while there was no significant sequence
homology of TTSuV1a or -1bORF1with TTSuV2ORF1, we iden-
tified two putative antigenic sites on ORF1 that are shared by
TTSuV1a and TTSuV1b (Fig. 8).
In addition, in this study, we also demonstrated the absence of
antigenic cross-reactivity between TTSuVs and a human geno-
group 1 TTV by IFA. Taken together, the results from this study
have important implications in predicting the antigenic cross-re-
TABLE 2 Reactivities of anti-TTSuV1a, anti-TTSuV1b, anti-TTSuV2,
prebleed rabbit, and anti-human TTV (AK47) sera in PCV1-free PK-15
cells transfected with plasmids encoding truncated ORF1 proteins from
TTSuV1a, TTSuV1b, and TTSuV2, respectively, as determined by IFA
Antibody
transfection
Antibody reactivitya
Anti-
TTSuV1a
Anti-
TTSuV1b
Anti-
TTSuV2
Prebleed
rabbit
serum
Anti-human
TTV (AK47)
pTri-1aORF1     
pTri-1bORF1     
pTri-2cORF1     
Mock     
a The intensity of the fluorescent signal was determined visually and is expressed as
ranging from to.
FIG 8 Comparison of hydrophilicity profiles of TTSuV1a (strain PTTV1a-VA) and TTSuV1b (strain PTTV1b-VA) ORF1 proteins and identification of two
putative common antigenic domains in ORF1 of TTSuV1. The C-terminal region used for the expression of the truncated 1a- or 1b-ORF1 is indicated by a box.
The corresponding alignment of amino acid sequences and amino acid positions of the two domains are also shown. Favorable mismatches of the amino acids
are displayed as colons, whereas neutral mismatches are depicted as periods.
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activities among different anelloviruses based on ORF1 amino
acid sequence homology. Currently, anelloviruses are classified
into nine genera according to the infected host species (human/
ape, tamarin, douroucouli, tupaia, pig, dog, and cat), nucleotide
sequence identity, and the genome size of primate anelloviruses
(TTV, TTMV [torque tenominivirus], and TTMDV [torque teno
midi virus]) (4). ORF1 of TTSuV (genus Iotatorquevirus) shares
15.6 to 22.3% amino acid sequence identity with the other eight
genera based on multiple-sequence alignments (data not shown),
which is similar to that between TTSuVs and human genogroup 1
TTV (19.1 to 21.0%). Therefore, it is reasonable to deduce that
porcine anellovirus is not antigenically cross-reactive with other
anelloviruses in other animal species. The ORF1 amino acid se-
quence homologies among the nine genera range from 15.0% to
27.3% (data not shown), thus implying that antigenic diversity
between different genera does exist.
The two TTSuV species (TTSuV1 and TTSuV2) do not share
antigenicity in theORF1 antigen since they had only 22.4 to 25.8%
amino acid sequence identity, whereas the two TTSuV1 genotypes
(TTSuV1a and -1b) were antigenically related and cross-reactive
due to their higher amino acid sequence homology (49.4 to
52.4%). It is possible that the antigenic relationship of different
anelloviruses in the same genus may depend on a threshold or a
range of amino acid sequence homologies. The available data us-
ing TTSuV as a model will provide insights into similar research
on the antigenic diversity of human anelloviruses (TTV, TTMV,
and TTMDV) in the future.
The present study of TTSuV1 together with our previous study
of TTSuV2 (14) also revealed a broader picture of the nature of
mixed TTSuV infections under natural or clinical disease condi-
tions by assessing serological and virological profiles. It is not sur-
prising to see in this study that several features of TTSuV1 infec-
tion were consistent with those of TTSuV2 (Fig. 3; see also Fig. S2
in the supplemental material) (14). More importantly, we pro-
vided new evidence to support the current opinion that TTSuV1 is
likely not associated with PCVAD (1, 19, 24), by demonstrating
that both viral loads and antibody levels were not significant dif-
ferent between PCVAD-affected and -unaffected pigs (Fig. 4; see
also Fig. S2 in the supplemental material) and that there was no
significant synergic PCV2/TTSuV1 effect. It is not knownwhether
the presence of the ORF1 antibody is protective against homolo-
gous TTSuV infection (14). However, since antibodies to TTSuV1
orTTSuV2ORF1donot cross-reactwith the heterologousTTSuV
antigen, it appears that TTSuV1 infection and the consequent hu-
moral immune response do not interfere with TTSuV2 infection.
Therefore, this may make the development of a single vaccine
against the two recognized TTSuV species difficult. Together, the
results from the present study have important implications in our
understanding of the diversity of anelloviruses and in diagnosis
and vaccine development for TTSuVs.
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